Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 8/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 8/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17232 | 0.92 | HSD11B1 (0.33) | HSD11B1KCNH2CYP3A4 | |
| SCHEMBL16497 | 0.92 | GCK (0.36) | GCKHSD11B1KCNH2CYP3A4 | |
| SCHEMBL17376 | 0.88 | GCK (0.43) | GCKHSD11B1KCNH2CYP3A4 | |
| SCHEMBL17495 | 0.85 | HSD11B1 (0.34) | HSD11B1KCNH2CYP3A4 | |
| SCHEMBL17846 | 0.85 | HSD11B1 (0.33) | HSD11B1KCNH2CYP3A4 | |
| SCHEMBL17321 | 0.83 | HSD11B1 (0.35) | GCKHSD11B1KCNH2CYP3A4 | |
| SCHEMBL16949 | 0.83 | HSD11B1 (0.31) | GCKHSD11B1KCNH2CYP3A4 | |
| SCHEMBL16912 | 0.82 | HSD11B1 (0.34) | GCKHSD11B1KCNH2CYP3A4 | |
| SCHEMBL16074 | 0.82 | HSD11B1 (0.34) | GCKHSD11B1KCNH2CYP3A4 | |
| SCHEMBL16815 | 0.82 | HSD11B1 (0.32) | HSD11B1KCNH2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2609081-A1 | SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | Amgen Inc. (US) | 2013-07-03 | — | — | EP | disclosed |
| WO-2012027261-A1 | SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | AMGEN INC. (US) | 2012-03-01 | — | — | WO | disclosed |